OPKO Health, Inc. (OPK)
NASDAQ$1.79
Market Cap
$1.2B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
77 of 924
Rank in Industry
4 of 49
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
OPK Insider Trading Activity
OPK Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $4,298,016 | 14 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| FROST PHILLIP MD ET AL | CEO & Chairman | 14 | $4.3M | 0 | $0 | $4.3M |
About OPKO Health, Inc.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers …
Insider Activity of OPKO Health, Inc.
Over the last 12 months, insiders at OPKO Health, Inc. have bought $4.3M and sold $0 worth of OPKO Health, Inc. stock.
On average, over the past 5 years, insiders at OPKO Health, Inc. have bought $9.32M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: FROST PHILLIP MD ET AL (CEO & Chairman) — $4.3M.
The last purchase of 200,000 shares for transaction amount of $347,820 was made by FROST PHILLIP MD ET AL (CEO & Chairman) on 2025‑03‑17.
List of Insider Buy and Sell Transactions, OPKO Health, Inc.
| 2025-03-17 | FROST PHILLIP MD ET AL | CEO & Chairman | 200,000 0.0286% | $1.74 | $347,820 | -1.10% | ||
| 2025-02-28 | FROST PHILLIP MD ET AL | CEO & Chairman | 67,434 0.0097% | $1.71 | $115,312 | +3.74% | ||
| 2025-01-28 | FROST PHILLIP MD ET AL | CEO & Chairman | 47,537 0.0069% | $1.47 | $70,060 | +12.33% | ||
| 2025-01-17 | FROST PHILLIP MD ET AL | CEO & Chairman | 150,000 0.022% | $1.47 | $220,425 | +12.41% | ||
| 2025-01-15 | FROST PHILLIP MD ET AL | CEO & Chairman | 500,000 0.0731% | $1.48 | $740,850 | +11.90% | ||
| 2024-12-13 | FROST PHILLIP MD ET AL | CEO & Chairman | 125,000 0.0182% | $1.59 | $199,375 | -0.31% | ||
| 2024-12-11 | FROST PHILLIP MD ET AL | CEO & Chairman | 500,000 0.0713% | $1.56 | $781,050 | +0.31% | ||
| 2024-11-29 | FROST PHILLIP MD ET AL | CEO & Chairman | 199,072 0.0291% | $1.53 | $305,376 | +2.60% | ||
| 2024-11-22 | FROST PHILLIP MD ET AL | CEO & Chairman | 100,000 0.0147% | $1.59 | $159,000 | 0.00% | ||
| 2024-11-14 | FROST PHILLIP MD ET AL | CEO & Chairman | 100,000 0.0146% | $1.62 | $161,980 | -2.47% | ||
| 2024-11-08 | FROST PHILLIP MD ET AL | CEO & Chairman | 280,183 0.0399% | $1.50 | $421,535 | +3.95% | ||
| 2024-05-23 | FROST PHILLIP MD ET AL | CEO & Chairman | 100,000 0.0142% | $1.27 | $126,937 | +17.97% | ||
| 2024-05-17 | FROST PHILLIP MD ET AL | CEO & Chairman | 163,997 0.0229% | $1.29 | $211,195 | +13.64% | ||
| 2024-03-18 | FROST PHILLIP MD ET AL | CEO & Chairman | 500,000 0.0725% | $0.87 | $437,100 | +71.00% | ||
| 2024-03-14 | FROST PHILLIP MD ET AL | CEO & Chairman | 500,000 0.0693% | $0.89 | $444,300 | +67.16% | ||
| 2024-03-13 | FROST PHILLIP MD ET AL | CEO & Chairman | 500,000 0.0723% | $0.93 | $463,750 | +60.45% | ||
| 2024-03-12 | FROST PHILLIP MD ET AL | CEO & Chairman | 600,000 0.0865% | $0.93 | $559,380 | +58.42% | ||
| 2024-02-28 | FROST PHILLIP MD ET AL | CEO & Chairman | 500,000 0.0718% | $0.99 | $496,150 | +49.16% | ||
| 2024-02-21 | FROST PHILLIP MD ET AL | CEO & Chairman | 1M 0.1283% | $0.99 | $991,700 | +44.55% | ||
| 2024-02-07 | FROST PHILLIP MD ET AL | CEO & Chairman | 1.5M 0.1855% | $0.98 | $1.46M | +45.00% |
Total: 1268
*Gray background shows transactions not older than one year
Insider Historical Profitability
9.69%
| FROST PHILLIP MD ET AL | CEO & Chairman | 213501448 31.7923% | $382.17M | 1154 | 0 | +10.65% |
| Frost Gamma Investments Trust | director | 198131694 29.5036% | $354.66M | 21 | 0 | <0.0001% |
| HSIAO JANE PH D | Vice Chairman & CTO | 27999880 4.1694% | $50.12M | 27 | 0 | +10.55% |
| Zerhouni Elias A. | Vice Chairman and President | 20327814 3.027% | $36.39M | 2 | 0 | +12.95% |
| Rubin Steven D | Executive VP-Administration | 6187732 0.9214% | $11.08M | 15 | 2 | +0.53% |
*Gray background shows insiders who have made transactions during last year
OPK Institutional Investors: Active Positions
| Increased Positions | 102 | +39.53% | 23M | +12.42% |
| Decreased Positions | 91 | -35.27% | 13M | -6.69% |
| New Positions | 35 | New | 4M | New |
| Sold Out Positions | 30 | Sold Out | 3M | Sold Out |
| Total Postitions | 269 | +4.26% | 199M | +5.72% |
OPK Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Rubric Capital Management Lp | $84,750.00 | 7.25% | 48.71M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $50,819.00 | 4.35% | 29.21M | -11,819 | -0.04% | 2024-12-31 |
| Blackrock, Inc. | $49,013.00 | 4.19% | 28.17M | -430,686 | -1.51% | 2024-12-31 |
| State Street Corp | $15,790.00 | 1.35% | 9.07M | +359,388 | +4.12% | 2024-12-31 |
| Geode Capital Management, Llc | $14,590.00 | 1.25% | 8.39M | +10,473 | +0.13% | 2024-12-31 |
| Ubs Group Ag | $8,392.00 | 0.72% | 4.82M | +4M | +469.79% | 2024-12-31 |
| Millennium Management Llc | $7,984.00 | 0.68% | 4.59M | +2M | +85.31% | 2024-12-31 |
| Goldman Sachs Group Inc | $6,681.00 | 0.57% | 3.84M | +1M | +40.02% | 2024-12-31 |
| Northern Trust Corp | $6,434.00 | 0.55% | 3.7M | +164,847 | +4.67% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $6,085.00 | 0.52% | 3.5M | -714,949 | -16.97% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.